Top Stories in Multiple Myeloma From ASH 2019

Joseph R. Mikhael, MD


January 02, 2020

Dr Joseph Mikhael, from the Translational Genomics Research Institute, City of Hope Cancer Center, discusses developments in therapy for relapsed or refractory multiple myeloma (RRMM), focusing on the CANDOR study, which demonstrated a 37% reduction in risk for progression or death with the addition of daratumumab to standard carfilzomib plus dexamethasone therapy.

In front-line therapy, Dr Mikhael focuses on the promising results from the GRIFFIN study. This phase 2 trial evaluated response rates of two induction regimens—bortezomib plus lenalidomide and dexamethasone (VRd) therapy compared with VRd plus daratumumab—in patients going on to have autologous stem cell transplant. The primary endpoint of stringent complete response was met with VRd plus daratumumab, showing superior results of 42% vs 37% on VRd alone.

For patients not having autologous stem cell transplant, Dr Mikhael discusses two more studies looking at the addition of daratumumab to existing regimens of ixazomib, lenalidomide, and dexamethasone. These included the phase 2 HOVON 143 and Mayo Clinic studies, which both reported improved response rates and progression-free survival with addition of daratumumab.

Among upcoming therapies, Dr Mikhael highlights the exciting potential of bispecific therapy targeting the B-cell maturation antigen (BCMA), presented by researchers from the University of Alabama.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.